Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of the Efficacy and the Safety of First Line Treatment With CHOP Plus Rituximab (R-CHOP) in Patients Aged 60 to 80 Years With Previously Untreated T-cell Angioimmunoblastic Lymphoma (AIL).

NCT00169156 is registered in ClinicalTrials.gov with Lymphoma Study Association as lead sponsor.

NCT NCT00169156
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00169156 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of the Efficacy and the Safety of First Line Treatment With CHOP Plus Rituximab (R-CHOP) in Patients Aged 60 to 80 Years With Previously Untreated T-cell Angioimmunoblastic Lymphoma (AIL).
Lead sponsor
Lymphoma Study Association
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2005
Completion date
November 30, 2012
Enrollment
27 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

untreated t-cell angioimmunoblastic lymphoma